Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 3/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.46 |
| ▸ | F2R | P25116 | 1/20 | 0.43 |
| ▸ | KLK1 | P06870 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 7/20 | 0.42 |
| ▸ | F2RL1 | P55085 | 4/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | FCER2 | P06734 | 2/20 | 0.41 |
| ▸ | F12 | P00748 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14486266 | 1.00 | KLKB1 (0.49) | KLKB1CPB2F2RKLK1CTSD | |
| SCHEMBL14485956 | 0.89 | KLKB1 (0.61) | KLKB1CPB2F2RKLK1CTSD | |
| SCHEMBL14485960 | 0.89 | KLKB1 (0.61) | KLKB1CPB2F2RKLK1CTSD | |
| SCHEMBL14486270 | 0.86 | CPB2 (0.43) | KLKB1CPB2KLK1CTSDF2RL1 | |
| SCHEMBL14485782 | 0.86 | KLKB1 (0.44) | KLKB1CPB2F2RKLK1CTSD | |
| SCHEMBL15901058 | 0.81 | KLKB1 (0.58) | KLKB1CPB2F2RKLK1MMP1 | |
| SCHEMBL14485573 | 0.81 | KLKB1 (0.58) | KLKB1CPB2F2RKLK1MMP1 | |
| SCHEMBL15901636 | 0.79 | KLKB1 (0.56) | KLKB1CPB2F2RKLK1F2RL1 | |
| SCHEMBL14485428 | 0.79 | KLKB1 (0.56) | KLKB1CPB2F2RKLK1F2RL1 | |
| SCHEMBL15901046 | 0.77 | KLKB1 (0.77) | KLKB1KLK1MMP1FCER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729443-B3 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-02-12 | — | — | EP | disclosed |
| US-9234000-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-01-12 | — | — | US | disclosed |
| EP-2729443-B1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-11-25 | — | — | EP | disclosed |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-08-13 | — | — | US | disclosed |
| US-9051249-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-20140213611-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, BDKRB1 | KLKB1 1/4885CPB2 46/4885F2R 29/4885 |
| US-20140213611-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, BDKRB1 | KLKB1 1/4885CPB2 46/4885F2R 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.